Consolidation with BV after high risk ASCT in R/R Hodgkin assoc with improved PFS irrespective of prior BV use. Real world data from Spanish group. Most benefit if PET+ prior to Tx. Retrospect data but largely backs up Aethera data. link.springer.com/article/10.100…

New paper⏩ What is next for #pirtobrutinib in #MCL? Check out our trial protocol manuscript for currently enrolling global RCT BRUIN MCL321: phase III study of pirtobrutinib vs investigator choice BTKi in BTKi naïve mantle cell lymphoma | Future Oncology futuremedicine.com/doi/10.2217/FO…

Former and current giants of CLL Catovsky - MartinDyer-

Yo 🫡 #pharmacology #MedStudentTwitter #MedTwitter

Patients ≥65 benefit from CART over planned chemo+transplant. In our ZUMA7 analysis median EFS was greater with CAR-T versus SOC (21.5 vs. 2.5 months HR, 0.276***) Median PFS was 21.5 v and 5.0m(HR, 0.384***) #lymsm bit.ly/3zltZcQ

Pirtobrutinib: First Approval #lymphoma #lymsm bit.ly/40PG5GO

Woah - big news. A PFS advantage of Nivo-AVD compared with BV-AVD in 1st line advanced Hodgkin Lymphoma! Can’t wait to see the presentation and publication.

UK NHSE Covid19 scheme Largest 1L series of BTKi in MCL to date #Ibrutinib +/-R in 1L #MCL high risk (HR) ≥1 TP53 mut/del, blastoid/pleomorph or Ki67%/MiB1 ≥30% N=149 35% HR mPFS for all 26m mPFS HR PFS 9.7m Work to do in high risk 1L MCL cBTKi+CD20 enough? #EHA2023 #lymsm

AutoSCT no more required for low risk r/r cHL > BV-Nivo salvage? Bradford Hoppe presented CheckMate 774 in #ASTRO2023 with 95% 3yPFS > RT consolidation with no AutoSCT in 28pts 5-30 ys. ILROG Team #radonc #hodgkin

Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy onlinelibrary.wiley.com/doi/10.1111/bj… #lymsm Martin Hutchings Wiley Oncology & Hematology

Invasive fungal infections following venetoclax and posaconazole co-administration onlinelibrary.wiley.com/doi/10.1111/bj… #leusm #TxID

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose? mdpi.com/1734350 #mdpicancers via Cancers MDPI #lymsm

No evidence of benefit with vitamin d supplementation in indolent lymphoma, and important question addressed by Jonathan Friedberg Wilmot Cancer Institute #ASH2023

New paper⏩ -Sadly a negative international trial despite real initial hope -So much more to do for pts with this awful dx #TPLL #lymsm Limited efficacy for ibrutinib & venetoclax in T-prolymphocytic leukemia:results from phase 2 international study ashpublications.org/bloodadvances/…

Delighted to share the results of our MARTA trial, just published in The Lancet Haematology. A collaborative effort of the German PCNSL Study Group. We are deeply thankful for the support of all collaborators and Else Kröner-Fresenius-Stiftung authors.elsevier.com/a/1iW3b_rV3GEO…

Update on the management of relapsed/refractory chronic lymphocytic leukemia #leusm

Announcing the International Prognostic Score for NLPHL (LP-IPS) in Journal of Clinical Oncology, the largest study of NLPHL to date. Congratulations to our founders Drs. Michael Sargent Binkley & Jamie Flerlage and the GLOW team on this high-impact publication. #NLPHLsm #lymsm ascopubs.org/doi/pdf/10.120…

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia ow.ly/3Vba50Roppr #HowITreat #lymphoidneoplasia

Fantastic to see the brilliant projects from our MED UEA UEA medical students and our Norfolk and Norwich University Hospitals and JPUH NHS FT junior colleagues presented at #BSH24 this week. Great representation of the work of the Norfolk haematology MDT.

AI comes to lymphoma response assessment! #lymsm ascopubs.org/doi/10.1200/JC…